keep recent strategi shift equity-for-product deal cosmo sub-
licens us right procedur sed byfavo acacia pharma npv cut
given current acacia stake futur byfavo mileston worth less
prior byfavo npv assum cosmo commercialis byfavo alon howev
could signific long-term valu cosmo multipl equiti stake
reflect current price henc buy pt
deal make strateg sens long-term upsid follow recent aemcolo
deal redhil byfavo remain cosmo sole near-term us commerci asset
redhil deal partnership byfavo seem like howev given
limit visibl time term valuat continu assum cosmo
would commercialis byfavo us acacia deal cosmo
secur mileston exceed owe paion overal estim worth
base unchang byfavo us sale togeth
acacia stake worth current level fall short
previou byfavo npv drive cut pt howev updat npv
reflect potenti long-term valu cosmo multipl equiti stake paion
redhil cassiopea acacia commerci near-commerci entiti
byfavo sub-licens acacia pharma ultra-short act sed byfavo
remimazolam expect approv us fda procedur sedat
april pdufa decis date keep equity-for-product strategi
cosmo sub-licens us byfavo right acacia pharma ahead acacia
potenti fda approv lead asset barhemsi feb pdufa decis date
barhemsi post-op nausea vomit acacia expect
similar target market byfavo cosmo receiv up-front acacia share
whilst also acquir share acacia stake byfavo
approv first sale cosmo receiv acacia
cash remaind cash share cosmo also provid loan
upon approv barhemsi byfavo commercialis acacia
owe commerci mileston plu royalti royalti match
cosmo owe paion june deal also includ
regulatori mileston paion assum would becom due
byfavo us approv sale
multipl product launch mb mmx phase trial start earli
aemcolo royalti partner redhil acceler year byfavo
royalti contribut assum fda approv april within
colonoscopi partner launch gi geniu europ
artifici intellig devic aid detect lesion colonoscopi
prepar underway us trial launch eleview
also distribut ww exclud japan canada cosmo
finalis protocol second confirmatori us phase trial methylen
blue mb mmx start
cosmo exclud except gains/loss
sale invest demerg entiti
pleas see analyst certif import disclosur inform inform regard statu non-u analyst
page report
cosmo exclud except gains/loss sale invest demerg entiti
cosmo aim leverag mmx colon drug deliveri
technolog maximis valu gi product
us market equity-for-product deal
demerg asset new entiti crystallis valu
lialda uceri ulcer coliti colonoscopi
rifafalk rifamycin sv mmx plu pipelin
share price base npv
posit poc data antibiot aemcolo/rifafalk
ibs-d gi indic could
gain eu approv methylen blue mmx
faster us trial anticip could
cassiopea share could rise toward upsid
scenario boost valu cosmo invest
month period catalyst togeth
number smaller event could boost npv
deriv price
prolong regulatori delay methylen blue mmx
discontinu could remov
byfavo regulatori concern delay approv
procedur sedat could remov
toward
downsid scenario lower valu cosmo
invest
month period setback could lower
npv deriv price
cosmo commit return profit
manag past
return excess cash sharehold anticip
manag execut equity-for-product right
deal and/or establish newco maximis
valu us commerci opportun tax effici
aemcolo/rifafalk phase ii data ibs-d
start second mb mmx phase trial
complet launch shortli thereaft
byfavo/remimazolam us approv around april
aemcolo latin america asia
pleas see import disclosur inform page report
retain buy price cut
cosmo leverag mmx colon drug deliveri technolog aim maximis
commerci opportun gi product lucr us market primarili
via equity-for-product out-licens deal success demerg swiss
list ipo dermatolog portfolio cassiopea end-jun anticip
cosmo could futur consid pursu similar strategi subsidiari us
gastrointestin gi restructur mb mmx setback aemcolo
out-licens redhil biopharma byfavo remimazolam acacia pharma
commerci right current retain mb mmx sinc incept manag
maintain effici cost structur typic out-licens late-stag drug
anticip remain ex-u strategi partner medtron commercialis eleview
aid remov polyps/adenoma artifici intellig modul gi
geniu aim improv detect rate colonoscopi npv sum-of-the-
part valuat continu suggest current share price undervalu potenti
lucr us gi commerci opportun upsid success new launch
potenti increment partnership deal
retain belief mb mmx potenti
sale forecast us
valuat per share probabl commerci success
news flow us phase initi eu approv around
row licens deal commercialis
methylen blue mmx novel diagnost assist colonoscopi procedur despit
need addit phase trial us scope design
discuss still regard mb mmx valuabl asset cosmo pipelin
potenti signific commerci opportun understand second trial
may differ endpoint first trial like focus non-polypoid adenoma
detect rate adr perhap enabl smaller faster trial
first mb mmx phase conduct year first patient
enrol februari headlin result disclos novemb follow
confirm second phase trial need month appeal process
assum second phase initi experi enabl
rapid complet could allow mb mmx re-fil
potenti approv european regulatori file submit februari
approv around
remain impress simplic product use mmx conveni appli
well-known dye methylen blue colon chromoendoscopi endoscopi use
intravit dye topic appli mucos surfac methylen blue select
absorb normal colon columnar cell dys-/neo-plast cell make ideal
assist diagnosi colon cancer premalign polyp dye
use year food addit somewhat limit use chromoendoscopi
manual applic prior procedur latter costli process intens
potenti messi clinician henc would expect conveni tablet form
mb mmx rapidli adopt
phase confirm mb mmx could reduc risk colon cancer
mb mmx met primari endpoint phase trial substanti improv
number subject least one histolog proven adenoma/carcinoma versu
high-definit white-light hdwl colonoscopi current gold standard care
vs baselin detect rate higher
pleas see import disclosur inform page report
assum like reflect expert site use trial nevertheless mb mmx
correctli identifi patient benefit typic
detect rate around ordinari clinic practic benefit mb mmx
could even profound broader endoscopi commun
importantli key secondari endpoint fals posit rate lower mb
mmx vs demonstr subject lesion requir
excis correctli identifi vs hdwl furthermor common cohort
requir excis patient detect rate vs
clinic relev view improv detect
non-polypoid flat lesion explain much benefit afford mb mmx
vs subject flag
phase trial enrol patient polyp hospit north america
europ number site increas acceler patient enrol
given rel oner protocol physician follow data integr
subject randomis mb mmx versu hdwl vs mb mmx
patient took standard bowel prepar
exhibit detail phase result confirm compel benefit mb mmx
jefferi research adapt cosmo present novemb
studi demonstr endoscopist adr significantli associ
risk interv colorect cancer screen colonscopi nejm bretagn et
al may adr vari substanti endoscopist rate europ report
increas adr associ decreas
risk cancer lower risk fatal interv nejm corley et al april
risk interv cancer subject assess endoscopist lowest
quintil adr twice highest quintil adr improv
least one quintil associ decreas incid interv cancer
lower risk death interv cancer kaminski ddw given
close correl risk cancer adr believ patient physician
payer motiv adopt mb mmx clinician feedback suggest mb
mmx highli like adopt colonoscopi guidelin heard
flaw concern surround product
us payer must cover screen colonoscopi out-of-pocket cost basic
procedur howev drug mb mmx would bill separ part
medicar understand patient typic spend out-of-pocket cover some/
pleas see import disclosur inform page report
mb mmxhdwlrrrp valuen full analysi set first time screen surveil colonoscopi year sinc surveil colonoscopi year sinc per protocol histolog proven adenoma/carcinoma adr adr per posit subject requir subject requir histolog proven non-polypoid diminut equiti research
cost conveni brand bowel prep solut may also
model mb mmx patients/physician motiv higher detect rate
believ impress phase data compel us payer grant mb
mmx favour formulari tier low co-pay may biggest factor
determin us peak sale potenti
estim us list price around averag revenu per procedur
premium price brand bowel prep outsid
us assum lower averag revenu per procedur current understand
endoscopi like utilis dye perhap rise expert
centr assum mb mmx boost adopt chromocolonscopi
us ex-u respect procedur per annum
adopt rate could modest overal number colonoscopi like
conserv particularli given nation programm rais awar primari
screen
believ distribut agreement could sign ex-u market potenti
regulatori approv obtain like country-by-countri region basi
exhibit chang forecast
pleas see import disclosur inform page report
price cut
price base npv sum-of-the-part valuat continu
offer potenti upsid current share price includ contribut
phase cancer asset given stage develop
exhibit cosmo sourc upsid potenti downsid risk
pleas see import disclosur inform page report
peakvalueadj valuechfindicationsal mn eurmn prob eurmn per sharelialda/mezavantulc rifamycin sv mmx infecti diarrhoea blue mmxchromoendoscopi solut polyp geniu artifici intellig cassiopea paion redhil dilut dilut sharedownsidep shareaemcolo/relafalk studi ibs-d sibo heposit blue mmx regulatori decisionseu approv expedit us phase us investmentachiev price target scenario investmentupsid scenario us fda decisionu exhibit cosmo catalyst
pleas see import disclosur inform page report
catalystskeyimportantthreatscosmoaemcolopotenti asia and/or latamdealstnfmabmmxphas i/ii beginsmb mmxchromoendoscopi eu approvalmb beginsaemcolophas ii ibs-d resultsbyfav approv procedur sedationgi geniusu approv launch mmx ip expir june mb mmxpotenti eu distribut solid tumour drf solid tumour drf catalystskeyimportantthreatscosmotnfmabmmxphas i/ii resultsmb datau re-filingmb mmxchromoendoscopi us approv launchaemcoloisss data sibo diverticul exhibit cosmo revenu model
pleas see import disclosur inform page report
